NCT02061761 2023-03-24A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesBristol-Myers SquibbPhase 1/2 Completed106 enrolled 27 charts